Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III, causing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (factor Xa), and to a lesser extent factors IXa, XIa, and XIIa, thereby preventing thrombus formation and extension.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Prophylaxis and treatment of venous thrombosis and pulmonary embolism,Treatment of atrial fibrillation with embolization,Prophylaxis and treatment of peripheral arterial embolism,Anticoagulant use in extracorporeal circulation (e.g., during hemodialysis, cardiopulmonary bypass),Unstable angina and non-ST-segment elevation myocardial infarction (off-label),Acute coronary syndromes (off-label)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
IV: Initial bolus of 80 units/kg, then 18 units/kg/hour continuous infusion. Adjust based on a PTT. Typical maintenance: 1300 units/hour for adult (70 kg).
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Mean 1-2 hours (dose-dependent: increases with dose due to saturable clearance; at 100 U/kg IV: ~1 hr; at 400 U/kg: ~2.5 hrs); clinical context: may be prolonged in hepatic/renal disease
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Heparin is metabolized by the liver and reticuloendothelial system. It is partially desulfated and depolymerized; some components are excreted unchanged in urine. Metabolism is dose-dependent and saturable at high doses.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal (primarily via saturable mechanism; small amount metabolized by liver and reticuloendothelial system; no biliary/fecal elimination of significance)
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Very high, ~95-98% (binds to antithrombin III, albumin, and other plasma proteins)
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
0.05-0.1 L/kg (confined to plasma volume; low Vd due to high protein binding and large molecular size)
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
SC: 20-30% (variable based on injection site and depth); IV: 100%
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No specific GFR-based dose adjustment required; monitor a PTT and adjust accordingly. Accumulation not significant due to large molecular weight and extensive protein binding.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific Child-Pugh based modifications. Heparin clearance may be reduced in severe hepatic impairment; monitor coagulation parameters closely.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
IV: Bolus 75-100 units/kg over 10 minutes, then continuous infusion: Infants: 28 units/kg/hour; Children >1 year: 20 units/kg/hour; Adolescents: 18 units/kg/hour. Titrate to target a PTT (usually 60-85 seconds).
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Elderly patients (≥65 years) may have reduced heparin clearance; use lower initial infusion rates (e.g., 15 units/kg/hour) and monitor a PTT frequently to avoid over-anticoagulation.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Heparin is not intended for intramuscular use. There is an increased risk of bleeding complications. Monitor platelet counts regularly; heparin-induced thrombocytopenia (HIT) can occur. Use with caution in patients with history of HIT. Preservative-free heparin should be used in neonates and infants.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Monitor for signs of bleeding (hematuria, melena, easy bruising, epistaxis, etc.),Heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia with thrombosis (HITTS): discontinue heparin immediately if HIT suspected,Epidural or spinal catheter use: risk of spinal or epidural hematoma with concurrent anticoagulants,Hyperkalemia due to aldosterone suppression (especially in elderly, diabetic, renally impaired),Osteoporosis with prolonged use (>1 month),Hypersensitivity reactions including urticaria, angioedema, anaphylaxis
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to heparin or any component,History of heparin-induced thrombocytopenia (HIT) or HITTS,Active major bleeding (e.g., GI bleeding, intracranial hemorrhage),Severe thrombocytopenia (platelet count <100,000/mm³),Use of intramuscular injections while on heparin,Uncontrollable bleeding diathesis (e.g., hemophilia, severe liver disease)
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No significant food interactions. However, avoid excessive intake of foods high in vitamin K (e.g., leafy green vegetables, broccoli, Brussels sprouts) unless consistent consumption pattern is maintained, as vitamin K can antagonize heparin's effect indirectly. Alcohol may increase bleeding risk and should be limited.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Heparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations reported. Risk of hemorrhage at delivery.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Heparin is not excreted into breast milk due to high molecular weight. Compatible with breastfeeding. M/P ratio not applicable (not measurable).
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may require higher doses to achieve therapeutic a PTT. Dose adjustment based on a PTT monitoring advised.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Heparin sodium 10,000 units in 0.45% sodium chloride is a high-concentration infusion typically used for continuous intravenous administration in acute thrombotic events or prophylaxis. Confirm compatibility with all IV lines and medications; avoid concurrent use with other anticoagulants without clear indication. Monitor a PTT closely, targeting 1.5-2.5 times control for therapeutic effect. Rapid reversal requires protamine sulfate (1 mg per 100 units heparin). Use with caution in renal impairment, elderly, and patients with history of heparin-induced thrombocytopenia (HIT). Check platelet counts every 2-3 days to detect HIT early. Weight-based dosing is standard; this formulation is often used for bolus administration or infusion in fluid-restricted patients.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
You will receive this medication through an IV line to prevent or treat blood clots.,You may experience bruising or bleeding more easily; report any unusual bleeding, dark stools, or blood in urine immediately.,Avoid taking aspirin, ibuprofen, or other NSAIDs unless prescribed by your doctor, as they increase bleeding risk.,Inform all healthcare providers (including dentists) that you are taking heparin.,Do not discontinue the medication suddenly; it will be tapered as directed by your doctor.,You may be required to have regular blood tests (a PTT, platelet count) to monitor the drug's effect.,Notify your doctor immediately if you develop chest pain, shortness of breath, or signs of allergic reaction (rash, difficulty breathing).
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Heparin binds to antithrombin III, causing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (factor Xa), and to a lesser extent factors IXa, XIa, and XIIa, thereby preventing thrombus formation and extension.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% is: IV: Initial bolus of 80 units/kg, then 18 units/kg/hour continuous infusion. Adjust based on a PTT. Typical maintenance: 1300 units/hour for adult (70 kg).. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% is classified as Category A/B. Heparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations reported. Risk of hemorrhage at delivery.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.